CompletedNot Applicable

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Japan353 participantsStarted 2014-12-05

Plain-language summary

The objectives of this study are to investigate the safety and effectiveness of EYLEA.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who start EYLEA treatment for mCNV(myopic choroidal neovascularization). Exclusion Criteria: * Patients who have already received EYLEA treatment.

What they're measuring

Number of episodes of Adverse drug reaction (ADR's)

Timeframe: Up to 12 months

Number of episodes of Infections

Timeframe: Up to 12 months

Number of episodes of Serious Adverse Events(SAE's)

Timeframe: Up to 12 months

Number of episodes of Ocular Adverse events

Timeframe: Up to 12 months

Trial details

NCT IDNCT02260687

SponsorBayer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-04-02

View on ClinicalTrials.gov More Choroidal Neovascularization trials